{"nctId":"NCT01353313","briefTitle":"Hydrocortisone for BPD","startDateStruct":{"date":"2011-08-11","type":"ACTUAL"},"conditions":["Infant, Newborn","Infant, Small for Gestational Age","Infant, Very Low Birth Weight","Infant, Premature","Bronchopulmonary Dysplasia"],"count":800,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Hydrocortisone","type":"EXPERIMENTAL","interventionNames":["Drug: Hydrocortisone"]}],"interventions":[{"name":"Hydrocortisone","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* infants \\<30 weeks estimated gestational age\n* inborn at an NRN site or were admitted to an NRN site before 72 hours postnatal age\n* have received at least 7days of mechanical ventilation;\n* are receiving mechanical ventilation through an endotracheal tube .\n\nExclusion Criteria:\n\n* Major congenital anomalies\n* Decision to limit support\n* Indomethacin or ibuprofen treatment within 48 hours of study drug\n* Previous corticosteroid treatment for BPD\n* Received hydrocortisone for 14 or more cumulative days\n* Received hydrocortisone within 7 days of study entry","healthyVolunteers":false,"sex":"ALL","maximumAge":"30 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Survival Without Moderate/Severe Physiologic Bronchopulmonary Dysplasia (BPD)","description":"Survival without moderate or severe physiologic BPD at 36 weeks postmenstrual age. Moderate or severe physiologic BPD is defined as a requirement for supplemental oxygen and/or positive airway pressure to maintain oxygen saturation greater than 90 percent. A room air challenge was performed for infants estimated to be receiving less than 0.30 FiO2 by nasal cannula.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"332","spread":null},{"groupId":"OG001","value":"349","spread":null}]},{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"PRIMARY","title":"Survival Without Moderate/Severe Neurodevelopmental Impairment (NDI)","description":"Survival without moderate or severe neurodevelopmental impairment (NDI) at 22-26 months corrected age. NDI is defined as defined as any of: Bayley Scales of Infant and Toddler Development-III (Bayley-III) cognitive composite score less than 85 (standardized mean 100, SD 15, range 55-145) or motor composite score less than 85 (standardized mean 100, range 45-155) (lower scores indicating greater impairment), Gross Motor Function Classification System (GMFCS) level greater than or equal to II (on a scale from level I to V; I=normal and progressively higher levels indicate greater impairment), severe vision impairment in both eyes (consistent with refraction from less than 20 to 200), or bilateral hearing impairment with or without amplification (by report).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"226","spread":null},{"groupId":"OG001","value":"226","spread":null}]},{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"134","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Successful Extubation","description":"Successful extubation during the intervention period, defined as remaining extubated for greater than or equal to 1 week, including greater than or equal to 3 days after the last dose of study medication. An extubation attempt was required after 72 hours of study drug and 24 hours after meeting the following: FiO2 less than 0.40 to maintain a saturation of greater than or equal to 88 percent, mean airway pressure less than 8 cm H2O, and hemodynamically stable in the opinion of the clinical team.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"178","spread":null},{"groupId":"OG001","value":"135","spread":null}]},{"measurements":[{"groupId":"OG000","value":"220","spread":null},{"groupId":"OG001","value":"267","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Deaths Before Discharge","description":"Infant died before discharge home.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"40","spread":null}]},{"measurements":[{"groupId":"OG000","value":"363","spread":null},{"groupId":"OG001","value":"362","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Bronchopulmonary Dysplasia (BPD) Grade at 36 Weeks Postmenstrual Age","description":"BPD grade at 36 weeks postmenstrual age. BPD grades are defined as: 1. No support/room air; 2. Nasal cannula (NC) O2 less than or equal to 2L; 3. NC O2 greater than 2L or CPAP/NIPPV; 4. Invasive PPV","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"51","spread":null}]},{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"159","spread":null}]},{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"124","spread":null}]},{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Days of Mechanical Ventilation to 36 Weeks Postmenstrual Age (PMA)","description":"Number of days on mechanical ventilation (using high frequency ventilator or conventional ventilator)","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Oxygen Supplementation up to Status","description":"Number of days of oxygen supplementation from birth to discharge home","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104.5","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]}]},{"type":"SECONDARY","title":"Length of Hospital Stay in Days Among Survivors to Discharge","description":"Number of days infant stayed in hospitals, among those who survived to discharge","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127.5","spread":null},{"groupId":"OG001","value":"125.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Dexamethasone Given Before 36 Weeks Postmenstrual Age (PMA)","description":"Infant received dexamethasone anytime before 36 weeks postmenstrual age.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":null},{"groupId":"OG001","value":"157","spread":null}]},{"measurements":[{"groupId":"OG000","value":"229","spread":null},{"groupId":"OG001","value":"220","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Normal/Mild, Moderate or Severe/Profound NDI","description":"Severity of neurodevelopmental impairment, defined as one or more of: Bayley Scales of Infant Development-III (Bayley-III) cognitive score \\<85 (standardized mean 100, SD 15, range 55-145), Bayley-III motor score \\<85 (standardized mean 100, range 45-155), Gross Motor Function Classification System (GMFCS) level â‰¥2, severe vision impairment in both eyes (consistent with refraction \\<20-200), or bilateral hearing impairment with or without amplification (by report).\n\nBayley-III = Bayley Scales of Infant Development III (Cognitive score standardized mean 100, SD 15, range 55-145 motor score standardized mean 100, range 45-155; higher score indicates better performance (20))","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"98","spread":null}]},{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"134","spread":null}]},{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Gross Motor Function Greater Than or Equal to Level 2","description":"Number of infants with Gross Motor Function Classification System (GMFCS) level greater than or equal to II (on a scale from level I to V; I=normal and progressively higher levels indicate greater impairment)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"283","spread":null},{"groupId":"OG001","value":"288","spread":null}]},{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Moderate-severe Cerebral Palsy","description":"Number of infants with moderate or severe grade of cerebral palsy. Cerebral Palsy was diagnosed when there were definite abnormalities observed in the neuromotor exam, and functional challenges as classified by GMFCS level, and classified as moderate if GMFCS level was II or III and severe if level IV or V (40).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"33","spread":null}]},{"measurements":[{"groupId":"OG000","value":"289","spread":null},{"groupId":"OG001","value":"297","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Severe Hearing Impairment (by Report)","description":"Number of infants with bilateral hearing impairment with or without amplification (by report)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"319","spread":null},{"groupId":"OG001","value":"313","spread":null}]},{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With no/Some Functional Vision","description":"Number of infants with severe vision impairment in both eyes (consistent with refraction less than 20-200)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"325","spread":null},{"groupId":"OG001","value":"321","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Weight Growth Measure Following Extremely Preterm Birth","description":"This is measured as the weight Z-score at 36 weeks postmenstrual age. The Z-score is derived using Fenton growth curves, and follows a standardized normal distribution with a mean 0. A z-score of 0 designates average weight, and negative scores denote less than average weight.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.68","spread":"1.01"},{"groupId":"OG001","value":"-1.65","spread":"0.98"}]}]}]},{"type":"SECONDARY","title":"Follow-up Weight Growth Measure Following Extremely Preterm Birth","description":"This is measured as the weight Z-score at 22-26 months corrected age. The Z-score is determined using the WHO weight-for-age chart, and is derived from a standardized normal distribution, where 0 designates average weight-for-age, and negative scores denote less than average weight-for-age.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.51","spread":"1.04"},{"groupId":"OG001","value":"-0.44","spread":"1.15"}]}]}]},{"type":"SECONDARY","title":"Length Growth Measure Following Extremely Preterm Birth","description":"This is measured as the length Z-score at 36 weeks postmenstrual age. The Z-score is derived using Fenton growth curves, and follows a standardized normal distribution with a mean 0. A z-score of 0 designates average length, and negative scores denote less than average length.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.33","spread":"1.16"},{"groupId":"OG001","value":"-2.21","spread":"1.14"}]}]}]},{"type":"SECONDARY","title":"Follow-up Length Growth Measure Following Extremely Preterm Birth","description":"This is measured as the length Z-score at 22-26 months corrected age. The Z-score is determined using the WHO length-for-age chart, and is derived from a standardized normal distribution, where 0 designates average length-for-age, and negative scores denote less than average length-for-age.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.93","spread":"1.17"},{"groupId":"OG001","value":"-0.94","spread":"1.22"}]}]}]},{"type":"SECONDARY","title":"Head Circumference Growth Measure Following Extremely Preterm Birth","description":"This is measured as the head circumference Z-score at 36 weeks postmenstrual age. The Z-score is derived using Fenton growth curves, and follows a standardized normal distribution with a mean 0. A z-score of 0 designates average head circumference, and negative scores denote less than average head circumference.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.68","spread":"1.34"},{"groupId":"OG001","value":"-1.74","spread":"1.17"}]}]}]},{"type":"SECONDARY","title":"Follow-up Head Circumference Growth Measure Following Extremely Preterm Birth","description":"This is measured as the head circumference Z-score at 22-26 months corrected age. The Z-score is determined using the WHO head circumference-for-age chart, and is derived from a standardized normal distribution, where 0 designates average head circumference-for-age, and negative scores denote less than average head circumference-for-age.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.45","spread":"1.41"},{"groupId":"OG001","value":"-0.35","spread":"1.42"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Bronchopulmonary Dysplasia (BPD) Grade 40 Weeks Postmenstrual Age","description":"BPD grade at 40 weeks postmenstrual age. BPD grades are defined as: 1. No support/room air; 2. Nasal cannula (NC) O2 less than or equal to 2L; 3. NC O2 greater than 2L or CPAP/NIPPV; 4. Invasive PPV","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"38","spread":null}]},{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"65","spread":null}]},{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"129","spread":null}]},{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Days of Mechanical Ventilation up to Status","description":"Number of days on mechanical ventilation (using high frequency ventilator or conventional ventilator) up to status","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Oxygen Supplementation Among Survivors to 36 Weeks","description":"Number of days of oxygen supplementation from birth to 36 weeks post menstrual age","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Invasive Positive Pressure Ventilation (PPV) After Postnatal Day 14","description":"Number of days on invasive PPV after postnatal day 14","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Non-invasive Positive Pressure Ventilation (PPV) (Nasal IPPV/CPAP) After Postnatal Day 14","description":"Number of days of non-invasive PPV after postnatal day 14","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Received Inhaled Glucocorticoids During Study Period","description":"Number of infants who received Inhaled glucocorticoids during the study intervention period","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"345","spread":null},{"groupId":"OG001","value":"355","spread":null}]},{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Received Other Systemic Glucocorticoids During Study Period","description":"Number of infants who received other systemic glucocorticoids during the study intervention period","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"342","spread":null},{"groupId":"OG001","value":"334","spread":null}]},{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days Dexamethasone Given Before 36 Weeks PMA","description":"Number of days infant received dexamethasone anytime before 36 weeks postmenstrual age.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Patent Ductus Arteriosus (PDA) Treated With Medication or Surgery","description":"Number of infants with a Patent Ductus Arteriosus (PDA) that was treated with medicine or surgery","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"206","spread":null},{"groupId":"OG001","value":"209","spread":null}]},{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"193","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Diagnosed With Necrotizing Enterocolitis (NEC)","description":"Number of infants diagnosed with Necrotizing Enterocolitis (NEC)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"46","spread":null}]},{"measurements":[{"groupId":"OG000","value":"365","spread":null},{"groupId":"OG001","value":"356","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Retinopathy of Prematurity (ROP) Stage 3 or Worse","description":"Number of infants diagnosed with ROP stage 3 or worse in either eye. ROP stage 3 or worse is determined based on the extent of extraretinal fibrovascular proliferation. Higher stages of ROP indicate a worse outcome; the stages range from 1 for \"mild\" disease, to 5 for \"severe\" disease.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"116","spread":null}]},{"measurements":[{"groupId":"OG000","value":"277","spread":null},{"groupId":"OG001","value":"260","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Receiving Therapy for Retinopathy of Prematurity (ROP)","description":"Number of infants receiving therapy for Retinopathy of prematurity (ROP)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"311","spread":null},{"groupId":"OG001","value":"293","spread":null}]},{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Severe Intraventricular Hemorrhage (IVH)","description":"Number of infants with severe IVH, grade 3 or 4. Severity of IVH is hierarchical. Grade 3 occurs when the ventricular size is enlarged and blood/echodensity is in the ventricle. Grade 4 occurs when blood/echodensity is in the parenchyma.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"316","spread":null},{"groupId":"OG001","value":"331","spread":null}]},{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Periventricular Leukomalacia","description":"Number of infants with Periventricular leukomalacia","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"376","spread":null},{"groupId":"OG001","value":"378","spread":null}]},{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Neurodevelopmental Impairment (NDI)","description":"Number of infants with NDI. NDI is defined as defined as any of: Bayley Scales of Infant and Toddler Development-III (Bayley-III) cognitive composite score less than 85 (standardized mean 100, SD 15, range 55-145) or motor composite score less than 85 (standardized mean 100, range 45-155) (lower scores indicating greater impairment), Gross Motor Function Classification System (GMFCS) level greater than or equal to II (on a scale from level I to V; I=normal and progressively higher levels indicate greater impairment), severe vision impairment in both eyes (consistent with refraction less than 20-200), or bilateral hearing impairment with or without amplification (by report).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null},{"groupId":"OG001","value":"185","spread":null}]},{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"134","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Bayley Scales of Infant Development (BSID) Cognitive Composite Score Less Than 85","description":"Number of infants with a BSID-III cognitive composite score less than 85. (standardized mean 100, SD 15, range 55-145). Higher scores indicate better performance. Composite BSID-III scores of less than 85 are less than 1 standard deviation below the mean of 100.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"176","spread":null}]},{"measurements":[{"groupId":"OG000","value":"150","spread":null},{"groupId":"OG001","value":"142","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Bayley Scales of Infant Development (BSID) Cognitive Composite Score Less Than 70","description":"Number of infants with a BSID-III cognitive composite score less than 70. (standardized mean 100, SD 15, range 55-145). Composite BSID-III scores of less than 70 are less than 2 standard deviations below the mean of 100.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"259","spread":null},{"groupId":"OG001","value":"269","spread":null}]},{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Bayley Scales of Infant Development (BSID) Motor Composite Score Less Than 85","description":"Number of infants with a BSID-III motor composite score less than 85. (standardized mean 100, SD 15, range 55-145). Composite BSID-III scores of less than 85 are less than 1 standard deviation below the mean of 100.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"158","spread":null}]},{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"152","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Bayley Scales of Infant Development (BSID) Motor Composite Score Less Than 70","description":"Number of infants with a BSID-III motor composite score less than 70. (standardized mean 100, SD 15, range 55-145). Composite BSID-III scores of less than 70 are less than 2 standard deviations below the mean of 100.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"241","spread":null},{"groupId":"OG001","value":"246","spread":null}]},{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Any Cerebral Palsy","description":"Number of infants with cerebral palsy. Cerebral Palsy was diagnosed when there were definite abnormalities observed in the neuromotor exam, and functional challenges as classified by GMFCS level, and classified as moderate if GMFCS level was II or III and severe if level IV or V (40).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"71","spread":null}]},{"measurements":[{"groupId":"OG000","value":"246","spread":null},{"groupId":"OG001","value":"259","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":84,"n":398},"commonTop":["Respiratory failure","Hypertension","Adrenal insufficiency neonatal","Nosocomial infection","Hyperglycaemia"]}}}